LANGUAGE
KOREAN
ENGLISH
LOCATION
COMPANY
R&D
R&D Institute
GMP Center
Clinical Development Status
Publications
PRODUCTS
1st Generation
Overview
CARTISTEM
®
PNEUMOSTEM
®
2nd Generation
Overview
SMUP-IA-01
SMUP-IV-01
R&D Inquiries
BUSINESS
CDMO
Quality System
CDMO Service
Quality Control
Global CDMO
CDMO Inquiries
CELLTREE Cord Blood Bank
MOVITA Nutritional Supplements
IR
Stock Information
Disclosure
Financial Information
IR Inquiries
PR
MEDIPOST on Media
Corporate Brochure
CONTACT US
Customer Center
R&D Inquiries
CDMO Inquiries
IR Inquiries
Search Results
MEDIPOST Registers US Patent for the Treatment of Lung Diseases
2019/04/17
MEDIPOST Clears Product Approval Renewal of CARTISTEM by the Ministry of Food an…
2019/03/26
MEDIPOST, acquires a Japanese patent for the mesenchymal stem cell culture metho…
2019/01/30
MEDIPOST, ends phase I and II clinical trials with PNEUMOSTEM, the effective tre…
2019/01/08
MEDIPOST signs a joint research agreement with LG Chemical
2019/01/07
MEDIPOST, signs a contract with SK Bioland for an ankle joint indication
2019/01/02
MEDIPOST acquires US Patent for the ‘Mesenchymal Stem Cell Culture Method…
2018/10/24
MEDIPOST acquires the patent in Mexico for ‘CARTISTEM’
2018/07/11
MEDIPOST acquires the Japanese patent in hair loss prevention and hair growth pr…
2018/07/04
MEDIPOST acquires patents on the “Mesenchymal Stem Cell Culture Method” in 6 Eur…
2018/06/27
Significant increase in the revenue of MEDIPOST stem cell therapeutics CARTISTEM…
2018/04/20
MEDIPOST, selected as a “Excellent Disclosure Corporation” by the Korea Exchange
2018/04/18
Previous
1
…
4
5
6
7
8
9
10
…
14
Next
Menu